SCHEMBL1206248

SCHEMBL1206248

COc1cccc(CCCCC(=O)O)c1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.70
HDAC6 Q9UBN7 1/20 0.70
MTNR1A P48039 2/20 0.61
MTNR1B P49286 2/20 0.61
MAPT P10636 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
CYP1A2 P05177 1/20 0.56
PPARG P37231 1/20 0.56
PPARA Q07869 1/20 0.56
PTGFR P43088 1/20 0.56
CHRM2 P08172 1/20 0.55
CHRM1 P11229 1/20 0.55
CHRM3 P20309 1/20 0.55
TAAR1 Q96RJ0 1/20 0.54
CYSLTR2 Q9NS75 1/20 0.54
CYSLTR1 Q9Y271 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28188589 1.00 HDAC1 (0.70) HDAC1HDAC6MTNR1AMTNR1BMAPT
SCHEMBL17274767 0.98 HDAC1 (0.72) HDAC1HDAC6MTNR1AMTNR1BMAPT
SCHEMBL710937 0.98 HDAC1 (0.72) HDAC1HDAC6MTNR1AMTNR1BMAPT
SCHEMBL9663074 0.98 HDAC1 (0.72) HDAC1HDAC6MTNR1AMTNR1BMAPT
SCHEMBL25035334 0.98 HDAC1 (0.72) HDAC1HDAC6MTNR1AMTNR1BMAPT
SCHEMBL7758273 0.95 HDAC1 (0.63) HDAC1HDAC6MTNR1AMTNR1BCYP1A2
SCHEMBL29669893 0.95 HDAC1 (0.63) HDAC1HDAC6MTNR1AMTNR1BCYP1A2
SCHEMBL28189252 0.94 PPARA (0.65) HDAC1HDAC6MTNR1AMTNR1BPPARG
Heptane SCHEMBL28189233 0.93 PPARA (0.67) HDAC1HDAC6MTNR1AMTNR1BPPARG
SCHEMBL346302 0.89 FFAR1 (0.65) HDAC1HDAC6MTNR1AMTNR1BCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-11253596-B2 Phenylalkylcarboxylic acid delivery agents NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2022-02-22 US claimed
US-20200405863-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS NOVO NORDISK A/S (DK) 2020-12-31 US claimed
CN-107501061-A A kind of preparation method of the ketone of 2 methoxyl group, 6,7,8,9 tetrahydro benzo cycloheptane 5 爱斯特(成都)生物制药股份有限公司 2017-12-22 CN claimed
EP-2114145-B1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECH INC (US) 2017-11-01 EP claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US claimed
CN-106456662-A Compositions of pentosan polysulfate for oral administration and methods of use thereof 奥利金制药公司 2017-02-22 CN claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP claimed
CN-105233294-A Phenylalkylcarboxylic acid delivery agent EMISPHERE TECH INC 2016-01-13 CN claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO claimed
US-20120258911-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2012-10-11 US claimed
US-20110046050-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2011-02-24 US claimed
CN-101616583-A Phenylalkylcarboxylic acid delivery agents EMISPHERE TECH INC 2009-12-30 CN claimed
EP-2114145-A2 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS Emisphere Technologies, Inc. (US) 2009-11-11 EP claimed
WO-2008112368-A2 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2008-09-18 WO claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO disclosed
US-11576981-B2 Acyl hydrazone linkers, methods and uses thereof ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2023-02-14 US disclosed
WO-2001002379-A1 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2001-01-11 WO disclosed
EP-1042320-A1 NEW COMPOUNDS WHICH ARE P2-PURINOCEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTOR ANTAGONISTS AstraZeneca UK Limited (GB) 2000-10-11 EP disclosed
WO-1999026944-A1 NEW COMPOUNDS WHICH ARE P2-PURINOCEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTOR ANTAGONISTS ASTRAZENEKA UK LIMITED (GB) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200405863-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS PGF, LIPA, PDGFA HDAC1 1777/4885HDAC6 613/4885MTNR1A 2265/4885
US-20110046050-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS PGF, LIPA, PDGFA HDAC1 1777/4885HDAC6 613/4885MTNR1A 2265/4885
US-11253596-B2 Phenylalkylcarboxylic acid delivery agents PGF, LIPA, PDGFA HDAC1 1777/4885HDAC6 613/4885MTNR1A 2265/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 HDAC1 1680/4885HDAC6 458/4885MTNR1A 2847/4885
US-20120258911-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS PGF, LIPA, PDGFA HDAC1 1777/4885HDAC6 613/4885MTNR1A 2265/4885
US-11576981-B2 Acyl hydrazone linkers, methods and uses thereof AADAC, HDAC8, KAT8 HDAC1 16/4885HDAC6 12/4885MTNR1A 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.